פרק 11: מהן ההשפעות השליליות החמורות והסכנות של התרופות הממריצות?

רשימת מקורות

  1. Frontline Interview with Russell Barkley. Interview Russell Barkley. Frontline | PBS (Public Broadcasting Service). Last Retrieved on November 16, 2021 from: https://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/barkley.html; Retrieved on November 2021.
  2. Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents–assessment of adverse events in non‐randomised studies. Cochrane Database of Systematic Reviews. 2018;(5)
  3. נובורטיס ישראל. עלון לצרכן לפי תקנות הרוקחים של תרופת הריטלין. נובורטיס פארמה, בזל, שווייץ. עלון זה נבדק ואושר על-ידי משרד הבריאות בפברואר 2017.; 2017.
  4. Drug Enforcement Administration (DEA). Controlled Substance Schedules. The U.S. Department of Justice. Last retrieved on September 5, 2023 from: https://www.deadiversion.usdoj.gov/schedules/; 2023.
  5. APA. Diagnostic and Statistical Manual of  Mental Disorders, 5th edition, Text Revision (DSM-5-TR). American Psychiatric Association.  Washington, DC; 2022.
  6. Hidaka BH. Depression as a disease of modernity: Explanations for increasing prevalence. Journal of Affective Disorders. 2012/11/01/ 2012;140(3):205-214. doi:https://doi.org/10.1016/j.jad.2011.12.036
  7. Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis. https://doi.org/10.1111/bjc.12333. British Journal of Clinical Psychology. 2022/06/01 2022;61(2):287-305. doi:https://doi.org/10.1111/bjc.12333
  8. Rossen LM, Hedegaard H, Khan D, Warner M. County-level trends in suicide rates in the US, 2005–2015. American journal of preventive medicine. 2018;55(1):72-79.
  9. Mishara BL, Stijelja S. Trends in US Suicide Deaths, 1999 to 2017, in the Context of Suicide Prevention Legislation. JAMA Pediatrics. 2020;174(5):499-500. doi:10.1001/jamapediatrics.2019.6066
  10. Twenge JM, Joiner TE, Rogers ML, Martin GN. Increases in Depressive Symptoms, Suicide-Related Outcomes, and Suicide Rates Among U.S. Adolescents After 2010 and Links to Increased New Media Screen Time. Clinical Psychological Science. 2018/01/01 2017;6(1):3-17. doi:10.1177/2167702617723376
  11. Ophir Y, Lipshits-Braziler Y, Rosenberg H. New-Media Screen Time is Not (Necessarily) Linked to Depression: Comments on Twenge, Joiner, Rogers, and Martin (2018). Clinical Psychological Science. 2019:2167702619849412. doi:10.1177/2167702619849412
  12. Orben A. Teenagers, screens and social media: a narrative review of reviews and key studies. Social Psychiatry and Psychiatric Epidemiology. 2020/01/10 2020;doi:10.1007/s00127-019-01825-4
  13. FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. U.S. Food and Drug Administration. Last retrieved on July 19, 2023 from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications; 2018.
  14. Spielmans GI, Spence-Sing T, Parry P. Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified. Review. Frontiers in Psychiatry. 2020-February-13 2020;11doi:10.3389/fpsyt.2020.00018
  15. Piper BJ, Ogden CL, Simoyan OM, et al. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PloS one. 2018;13(11):e0206100.
  16. Bruno S, Kiki C, Katia V. General practice database on mortality in adults on methylphenidate: cohort study. BMJ Open. 2022;12(8):e057303. doi:10.1136/bmjopen-2021-057303
  17. McCarthy S, Cranswick N, Potts L, Taylor E, Wong ICK. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment. Drug safety. 2009;32(11):1089-1096.
  18. Ophir Y. Reconsidering the Safety Profile of Stimulant Medications for ADHD. Ethical Human Psychology and Psychiatry. 2022;24-1
  19. MHRA. Package Leaflet: Concerta® XL 27 mg prolonged-release tablets. The Medicines and Healthcare products Regulatory Agency (MHRA) of the UK. Last retrieved on June 21, 2024 from: https://mhraproducts4853.blob.core.windows.net/docs/f2453c2a5c18409f9f4c415809b36a067c08fb59; 2024.
  20. Torres-Acosta N, O’Keefe James H, O’Keefe Caroline L, Lavie Carl J. Cardiovascular Effects of ADHD Therapies. Journal of the American College of Cardiology. 2020/08/18 2020;76(7):858-866. doi:10.1016/j.jacc.2020.05.081
  21. Negrao BL, Crafford D, Viljoen M. The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder: cardiovascular topic. Cardiovascular journal of Africa. 2009;20(5):296-299.
  22. Tadrous M, Shakeri A, Chu C, et al. Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. JAMA Network Open. 2021;4(10):e2130795-e2130795. doi:10.1001/jamanetworkopen.2021.30795
  23. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and Risk of Serious Cardiovascular Events in Adults. American Journal of Psychiatry. 2012/02/01 2012;169(2):178-185. doi:10.1176/appi.ajp.2011.11010125
  24. Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S. Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. Journal of Clinical Psychopharmacology. 2018;38(5)
  25. Gould MS, Walsh BT, Munfakh JL, et al. Sudden Death and Use of Stimulant Medications in Youths. American Journal of Psychiatry. 2009/09/01 2009;166(9):992-1001. doi:10.1176/appi.ajp.2009.09040472
  26. Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience & Biobehavioral Reviews. 2018/04/01/ 2018;87:255-270. doi:https://doi.org/10.1016/j.neubiorev.2018.02.001
  27. Cheng A, Tithecott GA, Edwards WE, Johnston IG. The impact of the withdrawal of Adderall XR (long-acting mixed amphetamine salts) from the Canadian market on paediatric patients and their families. Paediatrics & Child Health. 2007;12(5):373-378.
  28. Cortese S, Coghill D, Santosh P, Hollis C, Simonoff E. Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. The Lancet Child & Adolescent Health. 2020;4(6):e15.
  29. Merzon E, Manor I, Rotem A, et al. ADHD as a Risk Factor for Infection With Covid-19. Journal of Attention Disorders. 2021/11/01 2020;25(13):1783-1790. doi:10.1177/1087054720943271
  30. Merzon E, Weiss MD, Cortese S, et al. The Association between ADHD and the Severity of COVID-19 Infection. Journal of Attention Disorders. 2021:10870547211003659. doi:10.1177/10870547211003659
  31. רשת 13. אנשים עם הפרעות קשב וריכוז – בסיכון גבוה לחלות בקורונה. רשת 13, העולם הבוקר. נדלה לאחרונה בתאריך 19.7.23 מאתר: https://13tv.co.il/item/news/haolam-haboker/season-01/clips/aemsj-2042106/; 2020.
  32. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020/08/01 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
  33. Rivera-Izquierdo M, del Carmen Valero-Ubierna M, R-delAmo JL, et al. Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: A retrospective observational study. PloS one. 2020;15(6):e0235107.
  34. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. https://doi.org/10.1002/jmv.26389. Journal of Medical Virology. 2021/02/01 2021;93(2):1045-1056. doi:https://doi.org/10.1002/jmv.26389
  35. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-1655.
  36. Whitely M. The rise and fall of ADHD child prescribing in Western Australia: Lessons and implications. Australian & New Zealand Journal of Psychiatry. 2012/05/01 2012;46(5):400-403. doi:10.1177/0004867412444864
  37. Amour MDS, O’Leary DD, Cairney J, Wade TJ. What is the effect of ADHD stimulant medication on heart rate and blood pressure in a community sample of children? Canadian Journal of Public Health. 2018/06/01 2018;109(3):395-400. doi:10.17269/s41997-018-0067-0
  38. Zhang L, Li L, Andell P, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA psychiatry. 2024;81(2):178-187.
  39. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. European Neuropsychopharmacology. 2013/06/01/ 2013;23(6):534-541. doi:https://doi.org/10.1016/j.euroneuro.2012.06.011
  40. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2007;120(6):e1494-e1501.
  41. Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. Journal of child and adolescent psychopharmacology. 2014;24(6):302-310.
  42. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do Stimulants Protect Against Psychiatric Disorders in Youth With ADHD? A 10-Year Follow-up Study. Pediatrics. 2009;124(1):71. doi:10.1542/peds.2008-3347
  43. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123(2):611-616.
  44. Shyu Y-C, Yuan S-S, Lee S-Y, et al. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophrenia Research. 2015/10/01/ 2015;168(1):161-167. doi:https://doi.org/10.1016/j.schres.2015.08.033
  45. DelBello MP, Soutullo CA, Hendricks W, Niemeier RT, McElroy SL, Strakowski SM. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar disorders. 2001;3(2):53-57.
  46. Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. The Lancet Psychiatry. 2019;6(8):651-658.
  47. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. The Canadian Journal of Psychiatry. 1999;44(8):811-813.
  48. Cressman AM, Macdonald EM, Huang A, et al. Prescription stimulant use and hospitalization for psychosis or mania: a population-based study. Journal of clinical psychopharmacology. 2015;35(6):667.
  49. Castner SA, Goldman-Rakic PS. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology. 1999;20(1):10-28.
  50. Castner SA, Goldman-Rakic PS. Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates. Biological psychiatry. 2003;54(2):105-110.
  51. Hamard J, Rousseau V, Durrieu G, et al. Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults. BMJ Ment Health. 2024;27(1)
  52. Ney PG. Psychosis in a child, associated with amphetamine administration. Canadian Medical Association Journal. 1967;97(17):1026.
  53. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. American Journal of Psychiatry. 2006;163(7):1149-1152.
  54. Rashid J, Mitelman S. Methylphenidate and somatic hallucinations. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46(8):945-946.
  55. Curtin K, Fleckenstein AE, Keeshin BR, et al. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology. 2018;43(13):2548-2555.
  56. Harman GH. The inference to the best explanation. The philosophical review. 1965;74(1):88-95.
  57. del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biological psychiatry. 2011;69(12):e145-e157.
  58. Rosa-Neto P, Lou HC, Cumming P, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. NeuroImage. 2005/04/15/ 2005;25(3):868-876. doi:https://doi.org/10.1016/j.neuroimage.2004.11.031
  59. Pies RW. Debunking the two chemical imbalance myths, again. Psychiatric Times. 2019;36(8)
  60. Advokat C. Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD. Journal of Attention Disorders. 2007/07/01 2007;11(1):8-16. doi:10.1177/1087054706295605
  61. Diaz Heijtz R, Kolb B, Forssberg H. Can a therapeutic dose of amphetamine during pre-adolescence modify the pattern of synaptic organization in the brain? https://doi.org/10.1046/j.0953-816X.2003.03067.x. European Journal of Neuroscience. 2003/12/01 2003;18(12):3394-3399. doi:https://doi.org/10.1046/j.0953-816X.2003.03067.x
  62. Castner SA, Williams GV. From vice to virtue: Insights from sensitization in the nonhuman primate. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007/11/15/ 2007;31(8):1572-1592. doi:https://doi.org/10.1016/j.pnpbp.2007.08.026
  63. Robinson TE, Kolb B. Persistent Structural Modifications in Nucleus Accumbens and Prefrontal Cortex Neurons Produced by Previous Experience with Amphetamine. The Journal of Neuroscience. 1997;17(21):8491. doi:10.1523/JNEUROSCI.17-21-08491.1997
  64. Andreazza AC, Frey BN, Valvassori SS, et al. DNA damage in rats after treatment with methylphenidate. Progress in neuro-psychopharmacology and biological psychiatry. 2007;31(6):1282-1288.
  65. Motaghinejad M, Motevalian M, Shabab B, Fatima S. Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats. Journal of Neural Transmission. 2017/01/01 2017;124(1):121-131. doi:10.1007/s00702-016-1623-5
  66. Motaghinejad M, Motevalian M, Shabab B. Effects of chronic treatment with methylphenidate on oxidative stress and inflammation in hippocampus of adult rats. Neuroscience Letters. 2016/04/21/ 2016;619:106-113. doi:https://doi.org/10.1016/j.neulet.2015.12.015
  67. Moll GH, Hause S, Rüther E, Rothenberger A, Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. Journal of child and Adolescent Psychopharmacology. 2001;11(1):15-24.
  68. Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PloS one. 2012;7(3)
  69. Sax L. Boys adrift: The five factors driving the growing epidemic of unmotivated boys and underachieving young men. Basic Books; 2016.
  70. Li Y, Kauer JA. Repeated exposure to amphetamine disrupts dopaminergic modulation of excitatory synaptic plasticity and neurotransmission in nucleus accumbens. https://doi.org/10.1002/syn.10270. Synapse. 2004/01/01 2004;51(1):1-10. doi:https://doi.org/10.1002/syn.10270
  71. Marco EM, Adriani W, Ruocco LA, Canese R, Sadile AG, Laviola G. Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. Neuroscience & Biobehavioral Reviews. 2011;35(8):1722-1739.
  72. Bolanos CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ. Methylphenidate treatment during pre-and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biological psychiatry. 2003;54(12):1317-1329.
  73. Carlezon Jr WA, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biological psychiatry. 2003;54(12):1330-1337.
  74. Faraone SV. MYTH: ADHD medication is addictive. ADHD Awareness Month Last retrieved on November 30, 2023 from: https://wwwadhdawarenessmonthorg/therapeutic-use-of-stimulant-meds-for-adhd/. 2023;
  75. Steiner H, Van Waes V. Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Progress in neurobiology. 2013;100:60-80. doi:10.1016/j.pneurobio.2012.10.001
  76. Lambert NM. Stimulant treatment as a risk factor for nicotine use and substance abuse. 1998:
  77. FDA. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. FDA Drug Safety Communication. Last retrieved on May 12, 2023 from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions; 2023.
  78. Poulos CX, Cappell H. Homeostatic theory of drug tolerance: a general model of physiological adaptation. Psychological review. 1991;98(3):390.
  79. Lembke A. Dopamine nation: Finding balance in the age of indulgence. Penguin; 2021.
  80. Klaassen CE. Casarett and Doull's toxicology: the basic science of poisons. vol 71470514. McGraw-Hill.  Medical Publishiong Division.  New York; 2008.
  81. Spencer TJ, Biederman J, Madras BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biological psychiatry. 2005;57(11):1293-1300.
  82. Harris G, Carey B. Researchers fail to reveal full drug pay. New York Times: New York Times, Last retrieved on August 26, 2021 from:  https://www.nytimes.com/2008/06/08/us/08conflict.html; 2008.
  83. Lenzer J. Review launched after Harvard psychiatrist failed to disclose industry funding. BMJ. 2008;336(7657):1327. doi:10.1136/bmj.39609.364688.DB
  84. Quansah E. Molecular and Neurochemical Effects of Methylphenidate on the Developing Brain, Thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy. De Montfort University, United Kingdom; 2017.
  85. Quansah E, Zetterström TSC. Chronic methylphenidate preferentially alters catecholamine protein targets in the parietal cortex and ventral striatum. Neurochemistry International. 2019/03/01/ 2019;124:193-199. doi:https://doi.org/10.1016/j.neuint.2019.01.016
  86. Wang G-J, Volkow ND, Wigal T, et al. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PloS one. 2013;8(5)
  87. Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. Cochrane Database of Systematic Reviews. 2009;(2)
  88. Lerner A, Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain communications. 2019;1(1):fcz025.
  89. Schuckit MA, Daeppen J-B, Danko GP, et al. Clinical implications for four drugs of the DSM-IV distinction between substance dependence with and without a physiological component. American Journal of Psychiatry. 1999;156(1):41-49.
  90. Proebstl L, Kamp F, Manz K, et al. Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. European Psychiatry. 2019;59:15-24.
  91. Kantak KM, Dwoskin LP. Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD. Pharmacology, biochemistry, and behavior. 2016;145:24.
  92. Netflix. Painkiller. Netflix, Inc. US.; 2023.
  93. פרי מתיו. חברים, מאהבות והדבר הגדול הנורא. אור-עם ספרים. תרגום: נעמי גליק-עוזרד; 2023.
  94. Vastag B. Pay Attention: Ritalin Acts Much Like Cocaine. JAMA. 2001;286(8):905-906. doi:10.1001/jama.286.8.905
  95. Madjar N, Shlosberg D, Leventer-Roberts M, et al. Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence. European child & adolescent psychiatry. 2019:1-9.
  96. Blech J. Melancholy Without Shame (in German). DER SPIEGEL. Last retrieved on August 12, 2023 from: https://magazin.spiegel.de/EpubDelivery/spiegel/pdf/83865282; 2012.
  97. Farrell M, Martin NK, Stockings E, et al. Responding to global stimulant use: challenges and opportunities. The Lancet. 2019/11/02/ 2019;394(10209):1652-1667. doi:https://doi.org/10.1016/S0140-6736(19)32230-5

 

בחזרה לעמוד הראשי של רשימת המקורות של הספר, לחצו כאן. 

גלילה לראש העמוד
דילוג לתוכן